Riboxin, 20 mg/ml 5 ml 10 pcs

Pharmacotherapeutic group: metabolic agent.

CodeATH: [С01ЕВ].

Pharmacological properties:

Riboxin is a derivative (nucleoside) of purine, a precursor of adenosine phosphate ATP. It belongs to the group of drugs that stimulate metabolic processes. It has antihypoxic and antiarrhythmic effects. It increases myocardial energy balance, improves coronary circulation, prevents the consequences of intraoperative renal ischemia. It is directly involved in glucose metabolism and promotes metabolism in hypoxia and in the absence of ATP.

It activates pyruvic acid metabolism for normal tissue respiration and promotes activation of xanthine dehydrogenase. It stimulates the synthesis of nucleotides and enhances the activity of some Krebs cycle enzymes. By penetrating into cells, it has a positive effect on metabolic processes in the myocardium – it increases the force of heart contractions and promotes fuller myocardial relaxation in diastole, resulting in an increase in stroke volume. The mechanism of antiarrhythmic action is still unclear.

Reduces platelet aggregation, activates tissue regeneration (especially of the myocardium and the mucosa of the gastrointestinal tract).

Pharmacokinetics

Metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. A small amount is excreted in the urine.

Indications

Active ingredient

Composition

How to take, the dosage

Special Instructions

Contraindications

Side effects

Allergic reactions: skin itching, skin hyperemia (the drug should be discontinued). Rare: increase of uric acid concentration in blood, exacerbation of gout (with long-term use).

Similarities